`
`Pharmacyclics LLC - Ex. 2006
`Coalition for Affordable Drugs IV LLC v. Pharmacyclics LLC
`Case IPR2015-01076
`
`
`
`7/30/2015
`
`Ibruti nib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration | Johnson & Johnson
`Developmentand Janssen Biotech are part ofthe Janssen Pharmaceutical Companies ofJohnson & Johnson. Please visit
`http:llvwvw.janssenrnd.com for more information.
`
`###
`
`(This press release contains "fon/vard-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is
`cautioned not to rely on these fon/vard-looking statements. These statements are based on current expectations of future events. If
`underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the
`expectations and projections ofJanssen Research & Development, LLC, any of the other Janssen Phannaceutical Companies and/or
`Johnson & Johnson. Risks and uncertainties include, butare not limited to, general industry conditions and competition; economic
`factors, such as interest rate and currency exchange rate fiuctuations; technological advances, new products and patents attained by
`competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes
`in behavior and spending patterns or financial distress ofpurchasers ofhealthcare products and services; changes to governmental laws
`and regulations and domestic and foreign health care refonns; trends toward health care cost containment; and increased scrutiny of the
`healthcare industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in
`Exhibit 99 ofJohnson & Johnson’s Annual Report on Form 10-K for the fiscal yearended January 1, 2012. Copies of this Form 10-K, as
`well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None ofthe
`Janssen Pharmaceutical Companies nor Johnson & Johnson undertake to update any fon/vartl-looking statements as a result ofnew
`information or future events or developments).
`
`[1] PUBLIC LAW 1 12—144—JULY 9, 2012. U.S. Government Printing Office. Available at: http://www.gpo.gov/fdsys/pkg/PLAW-
`112pub|144/pdflPLAW-112pub|144.pdf
`[2] Waldenstrom Macroglobulinemia. American Cancer Society. Available at:
`http:l/vvww.cancer.org/cancerlvvaIdenstrommacroglobulinemiafindex.
`
`Media Inquiries:
`Kellie McLaughlin
`Phone: 1-908-927-7477
`Mobile: 1-609-468-8356
`
`Investor Relations:
`Stan Panasewicz
`Phone: 1-732-524-2524
`
`Louise Mehrotra
`Phone: 1-732-524-6491
`
`U.S. Medical Inquiries:
`1-800-JANSSEN (800-526-7736)
`
`Accessibility Sitemap
`
`PrivacyPo|icy Legal Notice Employees Employees Employees
`
` This site is governed solely by applicable U.S. law and governmental regulations. Please see our Privacy Policy. Use of this site
`
`constitutes your consent to application of such laws and regulations and to our Privacy Policy. Your use of the information on this
`site is subject to the terms of our Legal Notice. You should viewthe News section and the most recent SEC Filings in the Investor
`section in order to receive the most current information made available by Johnson & Johnson Services. Inc. Contact Us with any
`questions or search this site for more information.
`All contents © Copyright Johnson & Johnson Services, Inc.1997-2015. All Rights Reserved.
`
`Last Updated: 07/29/2015
`
`Exhibit 2006 Page 002
`http://vvww.jnj .com/news/alIlibrutinib-receives-two-oncology-breakthrough-therapy-designations-from-us-food-and-drug-administration
`
`2/2
`
`Exhibit 2006 Page 002
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
